Sankala Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Sankala Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.2K	Hold	64	–	–	0.03%	246
2026 Q1	$48K	Sell	64 -1	-2%	-$766	0.04%	235
2025 Q4	$50.8K	Buy	+65	New	+$44.1K	0.04%	228

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sankala Group's REGN Position: Q2 2026 in Review

Sankala Group held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 64 shares worth $52.2K. The position accounts for 0.03% of the portfolio, ranked #246.

Sankala Group first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. 1,338 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Sankala Group held 64 shares of Regeneron Pharmaceuticals worth $52.2K as of Q2 2026.
Sankala Group left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.03% of Sankala Group's portfolio in Q2 2026, its #246 holding.
Sankala Group first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
1,338 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.